|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
CA1271477A
(en)
|
1983-11-18 |
1990-07-10 |
John F. Gerster |
1h-imidazo[4,5-c]quinolin-4-amines
|
|
DE3346123A1
(de)
|
1983-12-21 |
1985-06-27 |
Janssen Pharmaceutica, N.V., Beerse |
Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
|
|
US4727064A
(en)
|
1984-04-25 |
1988-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Pharmaceutical preparations containing cyclodextrin derivatives
|
|
JPS61277612A
(ja)
*
|
1985-05-31 |
1986-12-08 |
Kiyoshi Morikawa |
接種用徐放性組成物
|
|
US6407079B1
(en)
|
1985-07-03 |
2002-06-18 |
Janssen Pharmaceutica N.V. |
Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
|
|
US4938949A
(en)
|
1988-09-12 |
1990-07-03 |
University Of New York |
Treatment of damaged bone marrow and dosage units therefor
|
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
|
US5736553A
(en)
|
1988-12-15 |
1998-04-07 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
|
|
EP0386960A3
(en)
*
|
1989-03-07 |
1991-10-23 |
American Cyanamid Company |
Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
|
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
|
US5037986A
(en)
|
1989-03-23 |
1991-08-06 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
|
|
NZ232740A
(en)
*
|
1989-04-20 |
1992-06-25 |
Riker Laboratories Inc |
Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
|
|
CA2044878C
(en)
*
|
1990-08-07 |
2000-12-26 |
Tacey X. Viegas |
Thermally reversible and irreversible gels
|
|
DK0553202T3
(da)
|
1990-10-05 |
1995-07-03 |
Minnesota Mining & Mfg |
Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
|
|
US5175296A
(en)
|
1991-03-01 |
1992-12-29 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
|
|
IL105325A
(en)
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
|
US5648516A
(en)
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US5525606A
(en)
|
1994-08-01 |
1996-06-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
|
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
|
US5693811A
(en)
|
1996-06-21 |
1997-12-02 |
Minnesota Mining And Manufacturing Company |
Process for preparing tetrahdroimidazoquinolinamines
|
|
US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
|
DE19637209B4
(de)
|
1996-09-12 |
2006-12-14 |
Siemens Ag |
Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
|
|
KR100518903B1
(ko)
|
1996-10-25 |
2005-10-06 |
미네소타 마이닝 앤드 매뉴팩춰링 캄파니 |
Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
|
|
JPH10298181A
(ja)
|
1997-04-25 |
1998-11-10 |
Sumitomo Pharmaceut Co Ltd |
タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
|
|
WO1999024432A1
(fr)
|
1997-11-12 |
1999-05-20 |
Mitsubishi Chemical Corporation |
Derives de purine et medicament les renfermant en tant qu'ingredient actif
|
|
NZ504800A
(en)
|
1997-11-28 |
2001-10-26 |
Sumitomo Pharma |
6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
|
|
JP4189048B2
(ja)
|
1997-12-26 |
2008-12-03 |
大日本住友製薬株式会社 |
複素環化合物
|
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
|
JP2000159767A
(ja)
|
1998-11-26 |
2000-06-13 |
Sumitomo Pharmaceut Co Ltd |
８−ヒドロキシアデニン誘導体の新規製造法
|
|
TR200101943T2
(tr)
|
1999-01-08 |
2002-04-22 |
3M Innovative Properties Company |
Bir immun cevap modifayeri ile mukoza ile ilgili durumların tedavisine yönelik formülasyonlar ve metodlar.
|
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
|
CZ27399A3
(cs)
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
|
IL131887A0
(en)
|
1999-09-14 |
2001-03-19 |
Dpharm Ltd |
Phospholipid prodrugs of anti-proliferative drugs
|
|
ATE322494T1
(de)
|
2000-01-07 |
2006-04-15 |
Universitaire Instelling Antwe |
Purin derivate, ihre herstellung und verwendung
|
|
JP3675274B2
(ja)
|
2000-01-27 |
2005-07-27 |
ダイソー株式会社 |
９−（２−ヒドロキシアルキル）プリン誘導体および１−（２−ヒドロキシアルキル）ピリミジン誘導体の製造法
|
|
GB2359747B
(en)
*
|
2000-02-29 |
2002-04-24 |
Maelor Pharmaceuticals Ltd |
Anaesthetic formulations
|
|
US6733764B2
(en)
|
2000-06-14 |
2004-05-11 |
Alain Martin |
Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
|
|
CA2352645A1
(en)
|
2000-07-28 |
2002-01-28 |
F. Hoffmann-La Roche Ag |
Compositions for dna transfection
|
|
AU2002212273B2
(en)
|
2000-09-15 |
2007-06-14 |
Aaron Diamond Aids Research Centre |
System and method for optimizing drug therapy for the treatment of diseases
|
|
GB0023008D0
(en)
|
2000-09-20 |
2000-11-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
|
US20020127224A1
(en)
|
2001-03-02 |
2002-09-12 |
James Chen |
Use of photoluminescent nanoparticles for photodynamic therapy
|
|
ATE348097T1
(de)
|
2001-04-09 |
2007-01-15 |
Chiron Corp |
Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
|
|
US7157465B2
(en)
|
2001-04-17 |
2007-01-02 |
Dainippon Simitomo Pharma Co., Ltd. |
Adenine derivatives
|
|
US7241890B2
(en)
|
2001-10-30 |
2007-07-10 |
Conforma Therapeutics Corporation |
Purine analogs having HSP90-inhibiting activity
|
|
GB0206461D0
(en)
|
2002-03-19 |
2002-05-01 |
Glaxo Group Ltd |
Improvements in vaccination
|
|
NZ538812A
(en)
|
2002-08-15 |
2009-02-28 |
3M Innovative Properties Co |
Immunostimulatory compositions and methods of stimulating an immune response
|
|
AU2003271064B2
(en)
|
2002-09-27 |
2010-06-17 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine compound and use thereof
|
|
JP2004137157A
(ja)
|
2002-10-16 |
2004-05-13 |
Sumitomo Pharmaceut Co Ltd |
新規アデニン誘導体を有効成分として含有する医薬
|
|
CA2512161A1
(en)
|
2003-01-28 |
2004-08-12 |
Shanghai Sunway Biotech Co., Ltd |
Hyperthermia oncolysis co-therapy
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
WO2005016235A2
(en)
|
2003-04-14 |
2005-02-24 |
The Regents Of The University Of California |
Combined use of impdh inhibitors with toll-like receptor agonists
|
|
US20050059613A1
(en)
|
2003-07-08 |
2005-03-17 |
Bahram Memarzadeh |
Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
|
|
KR20060054405A
(ko)
|
2003-07-31 |
2006-05-22 |
더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
암, 암의 발병 또는 암 증상의 치료, 예방 및/또는 개선용조성물 및 방법
|
|
WO2005020892A2
(en)
|
2003-08-08 |
2005-03-10 |
Mitochroma Research, Inc. |
Pharmaceutical compositions and methods for metabolic modulation
|
|
EP1667694B1
(en)
|
2003-09-05 |
2010-04-28 |
Anadys Pharmaceuticals, Inc. |
Tlr7 ligands for the treatment of hepatitis c
|
|
JP2005089334A
(ja)
|
2003-09-12 |
2005-04-07 |
Sumitomo Pharmaceut Co Ltd |
８−ヒドロキシアデニン化合物
|
|
KR20060070572A
(ko)
|
2003-09-18 |
2006-06-23 |
콘포마 세러퓨틱스 코포레이션 |
Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
|
|
FR2863890B1
(fr)
|
2003-12-19 |
2006-03-24 |
Aventis Pasteur |
Composition immunostimulante
|
|
JP2007526322A
(ja)
|
2004-03-02 |
2007-09-13 |
マサチューセッツ インスティテュート オブ テクノロジー |
ナノセル薬物送達系
|
|
US20070225303A1
(en)
|
2004-03-26 |
2007-09-27 |
Haruhisa Ogita |
8-Oxoadenine Compound
|
|
EP2269638A3
(en)
|
2004-05-28 |
2012-06-13 |
GlaxoSmithKline Biologicals S.A. |
Vaccine compositions comprising virosomes and a saponin adjuvant
|
|
CA2587676A1
(en)
|
2004-11-19 |
2006-05-26 |
Institut Gustave Roussy |
Improved treatment of cancer by double-stranded rna
|
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
|
JP2008526757A
(ja)
*
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤製剤および方法
|
|
CA2598076A1
(en)
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
|
DK1879893T3
(da)
|
2005-03-21 |
2010-09-13 |
Ferrer Int |
Fremgangsmåde til fremstilling af 1-substituerede 1H-imidazo[4,5-c]quinolin-4-aminforbindelser og mellemprodukter dertil
|
|
US20070292418A1
(en)
|
2005-04-26 |
2007-12-20 |
Eisai Co., Ltd. |
Compositions and methods for immunotherapy
|
|
EP1888587A1
(en)
|
2005-05-04 |
2008-02-20 |
Pfizer Limited |
2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
|
|
WO2007015877A2
(en)
|
2005-07-20 |
2007-02-08 |
Kalypsys, Inc. |
Inhibitors of p38 kinase and methods of treating inflammatory disorders
|
|
ES2577514T3
(es)
|
2005-08-22 |
2016-07-15 |
The Regents Of The University Of California |
Antagonistas de TLR
|
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
|
WO2007034917A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規なアデニン化合物
|
|
EP1939202A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
|
JPWO2007034881A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
KR20080059595A
(ko)
|
2005-09-27 |
2008-06-30 |
콜리 파마슈티칼 게엠베하 |
어댑터 올리고뉴클레오티드를 사용하는 ｔｌｒ-매개 면역반응의 조절
|
|
CN1947717B
(zh)
|
2005-10-14 |
2012-09-26 |
卓敏 |
选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
|
|
US20070100146A1
(en)
|
2005-11-03 |
2007-05-03 |
Trevor Dzwiniel |
Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
|
|
US20070264317A1
(en)
*
|
2006-05-15 |
2007-11-15 |
Perrigo Israel Pharmaceuticals Ltd. |
Imiquimod cream formulation
|
|
EP2029597A4
(en)
|
2006-05-31 |
2011-11-23 |
Univ California |
purine analogs
|
|
EP2038290B1
(en)
|
2006-07-07 |
2013-09-04 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
TW200831104A
(en)
|
2006-10-04 |
2008-08-01 |
Pharmacopeia Inc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
WO2008045529A1
(en)
|
2006-10-12 |
2008-04-17 |
Serenex, Inc. |
Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
|
|
CN101230064A
(zh)
|
2007-01-22 |
2008-07-30 |
靳广毅 |
9位亚甲基芳基上取代的嘌呤类衍生物
|
|
ES2552471T3
(es)
|
2007-02-07 |
2015-11-30 |
The Regents Of The University Of California |
Conjugados de agonistas de TLR sintéticos y usos de los mismos
|
|
US20100120799A1
(en)
|
2007-02-19 |
2010-05-13 |
Smithkline Beecham Corporation |
Purine derivatives as immunomodulators
|
|
EP2132209B8
(en)
|
2007-03-19 |
2014-04-16 |
AstraZeneca AB |
9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
|
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
|
WO2008118763A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Graceway Pharmaceuticals, Llc. |
Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
|
|
CA2691444C
(en)
|
2007-06-29 |
2016-06-14 |
Gilead Sciences, Inc. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
|
CN101129373B
(zh)
*
|
2007-08-16 |
2010-12-01 |
华中师范大学 |
一种制备咪喹莫特壳聚糖纳米粒的方法
|
|
WO2009035634A2
(en)
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
WO2009034386A1
(en)
|
2007-09-13 |
2009-03-19 |
Astrazeneca Ab |
Derivatives of adenine and 8-aza-adenine and uses thereof-796
|
|
MX2010007410A
(es)
*
|
2008-01-15 |
2011-02-25 |
Dow Pharmaceutical Sciences |
Formulacion de imiquimod.
|
|
EA201001264A1
(ru)
*
|
2008-02-07 |
2011-04-29 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
|
|
CN101239980B
(zh)
|
2008-02-18 |
2011-06-22 |
靳广毅 |
免疫受体调节剂偶联体前体和偶联体及其应用
|
|
WO2010088924A1
(en)
|
2009-02-06 |
2010-08-12 |
Telormedix Sa |
Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
|
|
KR20110117705A
(ko)
|
2009-02-11 |
2011-10-27 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
톨-유사 수용체 조정제 및 질병의 치료
|
|
EP2461690A4
(en)
|
2009-08-07 |
2013-03-27 |
Glaxosmithkline Biolog Sa |
LIPIDED OXOADENINE DERIVATIVES
|
|
US20130202629A1
(en)
|
2010-04-30 |
2013-08-08 |
The Regents Of The University Of California |
Uses of phospholipid conjugates of synthetic tlr7 agonists
|